Comparative Pharmacology
Head-to-head clinical analysis: ABREVA versus ADEFOVIR DIPIVOXIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABREVA versus ADEFOVIR DIPIVOXIL.
ABREVA vs ADEFOVIR DIPIVOXIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits viral DNA polymerase and DNA synthesis of herpes simplex virus (HSV-1 and HSV-2).
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Apply a thin layer to the affected area 5 times daily for 4 days.
10 mg orally once daily on an empty stomach.
None Documented
None Documented
Due to minimal systemic absorption, an elimination half-life cannot be accurately determined in humans. Following intravenous administration in animals, the terminal half-life is approximately 10 hours, but this is not clinically relevant for topical use.
Clinical Note
moderateAdefovir dipivoxil + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Clinical Note
moderateAdefovir dipivoxil + Tenofovir disoproxil
"The therapeutic efficacy of Tenofovir disoproxil can be decreased when used in combination with Adefovir dipivoxil."
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Docosanol is minimally absorbed after topical application; systemic absorption is negligible. Any absorbed drug is primarily metabolized and excreted via bile and feces. Renal excretion is insignificant. Less than 1% of the applied dose enters systemic circulation, and nearly all elimination occurs via biliary/fecal routes.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Category C
Category C
Antiviral
Antiviral